| Jenner Technologies, Inc. | |||
| Proposed Ticker: | JNR | 2010 Crow Canyon Place, Suite 100 | |
| Exchange: | American Stock Exchange | San Ramon, CA 94583 | |
| Industry: | Manufacturing (SIC Code 2834) | (510) 824-3150 | |
| Type of Shares: | Common Shares | Filing Date: | 2/19/97 | |
| U.S. Shares Filed: | 2,500,000 | Filing Range: | $7.00 - $8.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $18,750,000 | |
| Primary Shares: | 2,500,000 | Expenses: | $600,000 | |
| Secondary Shares: | 0 | Shares Out After: | 7,121,886 |
| Manager | Tier | Phone |
| National Securities Corp. | Lead Manager | (800) 800-9217 |
| Issuer's Law Firm: | Wilson, Sonsini, Goodrich & Rosati |
| Bank's Law Firm: | Orrick, Herrington & Sutcliffe |
| Auditor: | Ernst & Young |
| Registrar/Transfer Agent: | Continental Stock Transfer & Trust Co |
Dollar amounts in U.S. millions except for per share data | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/96 | 12/31/96 | ||||
| Revenue: | $2.21 | Assets: | $1.56 | ||
| Net Income: | -$2.69 | Curr Assets: | |||
| EPS: | -$0.56 | Liabilities: | $3.42 | ||
| Prior EPS: | Curr Liabilities: | ||||
| Cash Flow/Oper: | -$1.90 | Equity: | -$1.85 | ||
| Cash Flow/Fin: | Cash: | ||||
| Cash Flow/Inv: | |||||
| Business Description |
| The company, a development stage company, is engaged in the development of immunotherapies to treat patients with cancer and certain side effects related to chemotherapy. The company has four product candidates under development, two of which are in clinical trials. three of the company's product candidates are designed to delay or prevent the recurrence of cancer by stimulating the body's own immune system to attack microscopic disease remaining after a patient has undergone traditional therapy. The company's product candidates consist of macrophage activators and therapeutic vaccines. The company acquired the technology related to ACT and JT3002 through an exclusive worldwide license with Novartis AG. In addition, the company acquired the rights to produce the antigen related to OncoVax-P through a non-exclusive license with Research Corporation Technologies, Inc. and the antigen related to OncoVax-CL through an exclusive worldwide license with Eli Lilly & Company. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for research and development, clinical trials, purchase of equipment, working capital and general corporate purposes. |
| # of Units: | 2,500,000 | |||
| Unit Ticker: | - | Unit Price: | ||
| Warrant Ticker: | JNRW | Warrant Price: | $0.10 | |
| Warrant Exercise Date: | Warrant Exercise Price: | |||
| Warrant Expiration Date: | ||||
| Warrant Detachable: | Yes | Warrant Detach Date: | ||
| Warrant Callable: | No |
| Unit Composition: 1 Common Share + 1 Warrant |
| Warrant Entitlement: 1 Common Share |